Loading
A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZGGS18 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05584800 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 222 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-11-01. Interventions recorded: ZGGS18 for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/